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Abstract
Background: Increased numbers of myeloid-derived suppressor cells (MDSCs) are positively correlated with poor
prognosis and reduced survivals of cancer patients. They play central roles in tumor immune evasion and tumor
metastasis. However, limited data are available on phenotypic/transcriptomic characteristics of the different MDSCs
subsets in cancer. These cells include immature (I-MDSCs), monocytic (M-MDSCs), and polymorphonuclear/
granulocytic (PMN-MDSCs).
Methods: Phenotypic characterization of myeloid subsets from 27 colorectal cancer (CRC) patients was
assessed by flow cytometric analyses. RNA-sequencing of sorted I-MDSCs, PMN-MDSCs, and antigen-presenting
cells (APCs) was also performed.
Results: We found that the levels of I-MDSCs and PMN-MDSCs were increased in tumor tissues (TT),
compared with normal tissues (NT) in colorectal cancer. Our functional annotation analyses showed that
genes associated with histone deacetylase (HDAC) activation- and DNA methylation-mediated transcriptional
silencing were upregulated, and histone acetyl transferase (HAT)-related genes were downregulated in tumor-
infiltrating I-MDSCs. Moreover, pathways implicated in cell trafficking and immune suppression, including Wnt,
interleukin-6 (IL-6), and mitogen-activated protein kinase (MAPK) signaling, were upregulated in I-MDSCs.
Notably, PMN-MDSCs showed downregulation in genes related to DNA methylation and HDAC binding. Using
an ex vivo model, we found that inhibition of HDAC activation or neutralization of IL-6 in CRC tumor tissues
downregulates the expression of genes associated with immunosuppression and myeloid cell chemotaxis,
confirming the importance of HDAC activation and IL-6 signaling pathway in MDSC function and chemotaxis.
Conclusions: This study provides novel insights into the epigenetic regulations and other molecular pathways
in different myeloid cell subsets within the CRC tumor microenvironment (TME), giving opportunities to
potential targets for therapeutic benefits.
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Background
Colorectal cancer (CRC) is the third most common cancer
worldwide associated with high morbidity rates every year
[1]. Inflammation is recognized as a key driver for CRC
pathogenesis [2]. In inflammation-related cancers, myelo-
poiesis is disrupted and leads to accumulation of a hetero-
geneous population of myeloid cells, halted at varying
stages of maturation/differentiation and with a potent im-
munosuppressive activity, referred to as myeloid-derived
suppressor cells (MDSCs) [3, 4]. MDSCs express myeloid
markers but lack expression of MHC class II molecule,
HLA-DR, and are mainly divided into three phenotypically
distinct subpopulations; CD33+HLA-DR−/lowCD14−CD15−
early-stage, or immature MDSCs (e-MDSC/I-MDSC),
which consist of immature myeloid progenitors;
CD33+HLA-DR−/lowCD14+CD15− monocytic MDSCs (M-
MDSCs), which represent suppressive monocytes; and
CD33+HLA-DR−/lowCD14−CD15+ polymorphonuclear or
granulocytic MDSCs (PMN-MDSCs or G-MDSCs), which
are phenotypically distinct from mature neutrophils and
possess strong suppressive activity [3, 5–7].
MDSCs have been implicated in the pathogenesis of
cancer [5, 8], where they act as potent suppressors of T
cell-mediated responses against tumor cells within the
tumor microenvironment (TME) [8] and lymphoid organs
[9]. MDSCs enhance the progression of various types of
tumors by promoting immune suppression, cancer-
associated fibroblasts (CAF) activation, angiogenesis, and
tumor growth and metastasis [10] via the expression of
co-inhibitory receptors, such as PD-L1, and the release of
a vast array of molecules, such as arginase-1, inducible ni-
tric oxide synthase (iNOS), nitric oxide (NO), and reactive
oxygen/nitrogen species (ROS/RNS) [11, 12]. Additionally,
the number of circulating MDSCs has been positively cor-
related with poor prognosis and low survival rates in can-
cer patients, including those with CRC [13–15]. However,
limited studies have explored the molecular/functional
characteristics of different MDSC populations. In addition,
the underlying mechanisms behind gene transcriptional
regulation and signal transduction in these populations re-
main to be elucidated. Further insights into these mecha-
nisms could provide potential candidates to target MDSC
populations in cancer.
In this study, we performed flow cytometric analyses
of MDSC subpopulations in the CRC TME. The over-
view of the study design and analyses pipelines is
depicted in Fig. 1. We found that PMN-MDSCs and I-
MDSCs were higher in CRC tumor tissues, compared
with normal colon tissues. Moreover, the levels of these
cells were higher than M-MDSCs in the TME. Addition-
ally, we examined and transcriptomic profiling of I-
MDSCs and PMN-MDSCs in TT versus adjacent NT
using RNA-Seq analysis. We performed two-way com-
parisons of each population; firstly, we compared I-
MDSCs or PMN-MDSCs in TT with corresponding NT,
and secondly, we compared I-MDSCs or PMN-MDSCs
Fig. 1 Schematic representation of the study design and analysis tools. The flowchart represents the work flow (a) and bioinformatics pipeline
used in this study (b)
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in TT with APCs (the latter used as a control) in TT.
Interestingly, our functional pathway analyses showed
that epigenetic alterations, including DNA methylation
(a common epigenetic mechanism by which gene tran-
scription is repressed [16, 17]) and histone post-
translational modifications (mediated either by histone
deacetylases (HDACs) or histone acetyl transferases
(HATs) differ from one myeloid cell population to an-
other. Our RNA-Seq data showed that HDAC- and
DNA methylation-related genes were significantly upreg-
ulated in tumor-infiltrating I-MDSCs, while HAT-
related genes were downregulated. On the other hand,
HDAC- and DNA methylation-related genes were
significantly downregulated in tumor-infiltrating PMN-
MDSCs. Moreover, Wnt, IL-6, MAPK, SNARE, JNK,
and HIF-1 pathways were upregulated in tumor-
infiltrating I-MDSCs, suggesting their potential involve-
ment in cell differentiation and tumor progression. In
this study, we also investigated the involvement of
HDAC activation and IL-6 in regulating the suppressive
function of MDSCs using an ex vivo model. Of note, fur-
ther functional studies are warranted.
Results
Elevated levels of PMN-MDSCs and I-MDSCs in CRC tumor
tissues
It has been reported that tumor-infiltrating PMN-
MDSCs and I-MDSCs are expanded in colorectal tumor
tissue, compared with normal colon tissue [13]. Here,
we investigated the levels of PMN-MDSCs, I-MDSCs,
M-MDSCs, and APCs in TT, compared with NT from
the same CRC patients. The characteristic features of
the study population are shown in Table 1. We deter-
mined the level of the different myeloid cell subsets in
the TME (Fig. 2) and characterized their molecular/tran-
scriptomic profiles. Cells were isolated from NT and TT
of 27 CRC patients and flow cytometric analyses were
performed for their phenotypical characterization. We
did not find any significant differences in the relative
percentages between TT and NT of CD33+HLA-
DR−/lowCD14−CD15+ PMN-MDSCs (53.1 ± 4.2 vs 51.0 ±
3.7), CD33+HLA-DR−/lowCD14−CD15− I-MDSCs (40.5 ±
5.0 vs 40.9 ± 3.7), CD33+HLA-DR−CD14+ M-MDSCs
(3.8 ± 1.0 vs 6.8 ± 2.0), and CD33+HLA-DR+CD14+
APCs (34.3 ± 5.1 vs 36.6 ± 6.0) (Fig. 2a). Therefore, we
compared the absolute numbers of these subsets be-
tween TT and NT (Fig. 2a). We found that the absolute
numbers of PMN-MDSCs were significantly higher in
TT compared to NT (2272.0 ± 526.0 vs 1384.0 ± 383.5,
Fig. 2b). However, although the absolute numbers of I-
MDSCs were higher in TT compared to NT, the data
did not reach statistical significance (1467.0 ± 490.7 vs
975.8 ± 230.9, Fig. 2b). Moreover, there were no signifi-
cant differences in the absolute numbers of M-MDSCs
and APCs between TT and NT (Fig. 2b). In addition, we
compared the overall levels of PMN-MDSCs, I-MDSCs,
and M-MDSCs in TT and found that the relative per-
centages and absolute numbers of PMN-MDSCs,
followed by I-MDSCs were significantly higher than M-
MDSCs in the CRC TME (Fig. 2c). Visualization of the
different myeloid cell subsets in NT and TT is depicted
in Fig. 2d. We generated t-distributed stochastic neigh-
bor embedding (tSNE) plots for markers of myeloid cell
subsets and confirmed that PMN-MDSCs and I-MDSCs
were higher in TT, while APCs showed similar levels
and M-MDSCs were present at very low levels in NT
and TT.
Next, we selected six CRC patients to sort different
myeloid cell subpopulations (I-MDSCs, PMN-MDSCs,
and APCs) from TT and NT and analyze their transcrip-
tional profiling using RNA-Seq. However, the library
preparation and subsequent RNA-sequencing were suc-
ceeded from two patients only (#07 and #08). Gating
strategy for sorting these subpopulations from the two
patients is shown in Fig. 2e and f.
Genes associated with HDAC activation, DNA methylation,
and IL-6 signaling pathway are upregulated in tumor-
infiltrating I-MDSCs
A study showed that I-MDSCs can migrate into the
TME and differentiate into the highly immune suppres-
sive tumor-associated macrophages (TAMs) and con-
tribute to tumor progression by inhibiting the adaptive
anti-tumor immune response and enhancing tumor
growth/metastasis [18]. Here, we analyzed the differen-
tial gene expression in I-MDSCs isolated from TT, com-
pared with those isolated from NT. The hierarchal
clustering of differentially expressed transcripts showed
a distinct cluster of I-MDSCs in NT and TT (Fig. 3a and
Additional file 2: Table S1). Seven hundred ninety-eight
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upregulated and 637 downregulated transcripts were
identified in tumor-infiltrating I-MDSCs, compared with
those found in NT (with a fold of change > 2, P value
cutoff < 0.05). Functional annotation analyses showed
that upregulated genes are involved in histone deubiqui-
tination (6 genes), activation of Wnt signaling pathway
(4 genes), activation of IL-6 pathway (3 genes), activation
of MAPK signaling (5 genes), transcriptional repressors
(13 genes), DNA methylation (29 genes), and HDAC
activation (44 genes) (Fig. 3b, c and Additional file 3:
Table S2). Interestingly, epigenetic alterations such as
post-translational histone modifications were predomin-
ant in I-MDSCs (Fig. 3b, c). We found that 148 of up-
regulated genes in tumor-infiltrating I-MDSCs are
involved in HDAC activation and 50 upregulated genes
are associated with DNA methylation (Fig. 3b, c). Studies
showed that activation of IL-6 [19] and Wnt signaling
pathways [20] can promote the trafficking of MDSCs to
the TME. In line with this, our data showed that 10
genes associated with IL-6 pathway and 12 genes related
to Wnt signaling are significantly upregulated in tumor-
infiltrating I-MDSCs, compared with those found in NT
(Fig. 3b. c). This implies a potential role of IL-6 and
Wnt signaling pathways (Fig. 4a, b) in the biology of
tumor-infiltrating I-MDSCs. Notably, 112 genes related
to HAT activity and 12 genes related to myeloid differ-
entiation were significantly downregulated in tumor-
infiltrating I-MDSCs, compared with I-MDSCs in NT
(Fig. 3b, c).
Collectively, our data show that the transcriptional
profile of tumor-infiltrating I-MDSCs could be altered
by histone post-translational modifications induced by
HDAC activation, and/or DNA methylation. In addition,
we speculate that I-MDSCs promote tumorigenesis by
activating signaling pathways, such as Wnt and IL-6
pathways, which in turn enhance MDSCs recruitment to
the TME and support MDSCs suppressive function.
Genes associated with chemotaxis, cell migration, and
anti-apoptosis are upregulated in tumor-infiltrating PMN-
MDSCs
Next, we investigated the differential gene expression in
tumor-infiltrating PMN-MDSCs. It has been reported
that PMN-MDSCs expansion within the CRC tissue is
Fig. 2 Comparison of myeloid populations (PMN-MDSCs, I-MDSCs, M-MDSCs, and APCs) in NT and TT of CRC patients. Cells isolated from NT and
TT of 27 CRC patients were stained for myeloid cell markers and analyzed by flow cytometry. Scatter plots show the relative percentages of
CD33+HLA-DR−/lowCD14−CD15+ PMN-MDSCs, CD33+HLA-DR−/lowCD14−CD15− I-MDSCs, CD33+HLA-DR−/lowCD14+CD15− M-MDSCs, and
CD33+HLA-DR+CD14+ APCs in NT and TT from 27 CRC patients (a). Scatter plots show differences in absolute numbers of PMN-MDSCs, I-MDSCs,
M-MDSCs, and APCs in NT and TT from 27 CRC patients (b). Scatter plots show differences in relative percentages and absolute numbers of PMN-
MDSCs, I-MDSCs, and M-MDSCs in TT from 27 CRC patients (c). Flow cytometric data were merged to create single t-distributed stochastic
neighbor embedding (tSNE) maps to show PMN-MDSCs (denoted as PMN), I-MDSCs (denoted as I), M-MDSCs (denoted as M), and APCs in NT
and TT (d). Representative flow cytometric plots show the gating strategy employed to define and sort PMN-MDSCs, I-MDSCs, M-MDSCs, and
APCs from two CRC patients #07 (e) and #08 (f)
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positively correlated with advanced disease stages and
high histological grades, implying a role for PMN-
MDSCs in CRC progression [13]. The hierarchal cluster-
ing of differentially expressed transcripts showed a dis-
tinct cluster of PMN-MDSCs isolated from NT and TT
(Fig. 5a and Additional file 2: Table S1). Five hundred
seventy-six upregulated and 785 downregulated tran-
scripts were identified in tumor-infiltrating PMN-
MDSCs, compared with those found in NT (with a fold
of change > 2 and P value cutoff < 0.05). Within the up-
regulated transcripts of PMN-MDSCs, 5 genes were re-
lated to chemotaxis induction, 60 genes were related to
cell-cell signaling, 22 genes were related to anti-
apoptosis, 9 genes were related to cytokine-mediated sig-
naling, 20 genes were related to proliferation and 4
genes were related to epithelial migration (Fig. 5b, c and
Additional file 3: Table S2). Interestingly, 98 genes re-
lated to transcriptional regulation and 45 genes related
to DNA methylation were significantly downregulated in
tumor-infiltrating PMN-MDSCs, compared with those
found in NT (Fig. 5b, c). In addition, our functional net-
work analysis confirms that cell migration-related genes
were upregulated in the PMN-MDSCs subpopulation
found within the CRC microenvironment (Additional
file 1: Figure S1).
Transcriptional regulation in tumor-infiltrating I-MDSCs
and PMN-MDSCs is mediated via distinct epigenetic
mechanisms
Next, we investigated the differential expression of tran-
scripts in tumor-infiltrating I-MDSCs, compared to
APCs. The hierarchal clustering of gene transcripts is
depicted in Fig. 6a and Additional file 2: Table S1. We
found 1802 transcripts that were differentially expressed
in I-MDSCs. Out of 1802 transcripts, 1098 were signifi-
cantly upregulated and 704 were downregulated in I-
MDSCs (with a fold of change > 2 and P value cutoff <
0.05). Based on the network and functional annotation
analyses, 17 genes from Wnt signaling, 41 genes from
JNK pathway and 4 genes from SNARE complex activa-
tion were upregulated in tumor-infiltrating I-MDSCs
(Fig. 6b and Additional file 3: Table S2).
We also investigated the differences in the transcrip-
tional profile between tumor-infiltrating PMN-MDSCs
Fig. 3 Differential gene expression of I-MDSCs in CRC microenvironment. Hierarchical clustering of I-MDSCs from two TT and NT (from patients
#07 and 08) on differentially expressed RNA transcripts from RNA-Seq data. Each column represents a sample and each row represents a
transcript. Expression level of each gene in a single sample is depicted according to color scale (a). Functional categorization of both upregulated
and downregulated top significantly affected transcripts (P value < 0.05) from CLC analysis were analyzed through DAVID separately. The total
number of genes come under both downregulated and upregulated categories was used to calculate the percentage of genes come under
individual functional category. The bar diagram shows the percentage of genes present in each functional category (b). Heat maps show the
log2 of transcript per million (TPM) representing fold change relative to the mean expression of HDAC activation and transcriptional silence, DNA
methylation, and chromatin silencing and histone acetylation in TT, compared with NT (c)
Sasidharan Nair et al. Clinical Epigenetics           (2020) 12:13 Page 5 of 15
and APCs. The hierarchal clustering of PMN-MDSCs
and APCs is shown in Fig. 6c and Additional file 2:
Table S1. We found 1803 genes that were distinct in
PMN-MDSCs, compared with APCs. Out of 1803, 1098
genes were significantly upregulated and 705 were
downregulated in tumor-infiltrating PMN-MDSCs, com-
pared with APCs (with a fold of change > 2 and P value
cutoff < 0.05). Interestingly, 15 genes related to CRC
progression, 19 genes related to cell migration and 17
genes related to NF-kB/IL-1β-mediated recruitment of
MDSCs were upregulated in tumor-infiltrating PMN-
MDSCs (Fig. 6d and Additional file 3: Table S2). More-
over, 13 genes related to HDAC binding and 17 genes
related to DNA methylation were significantly downreg-
ulated in tumor-infiltrating PMN-MDSCs (Fig. 6d).
Together, these results suggest that upregulation of
Fig. 4 Functional network analysis of I-MDSCs in CRC microenvironment. The significantly upregulated genes in TT, compared with NT from 2
patients were uploaded in DAVID to identify the biological pathways. BioCarta pathway of IL-6 signaling pathway is identified in the enrichment
analysis with significant enrichment of upregulated genes with P < 0.05 (a). WNT signaling is the top KEGG pathway regulated in I-MDSCs,
compared with APCs within the TME (b). The black ovals highlight the KEGG identified functional pathways that are regulated by I-MDSCs, within
the TME. The red highlights without boxes show the functional consequences of related genes
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genes involved in cell migration and MDSCs recruitment
in tumor-infiltrating PMN-MDSCs may occur as a result
of HDAC inactivation and DNA demethylation.
Additionally, we compared the transcription profile
between tumor-infiltrating PMN-MDSCs and I-MDSCs.
The hierarchal clustering is shown in Fig. 6e and
Additional file 2: Table S1. We found that 1395 genes
were significantly distinct in tumor-infiltrating PMN-
MDSCs. Out of 1395, 633 genes were significantly
upregulated and 762 were downregulated in tumor-
infiltrating PMN-MDSCs. Functional annotation ana-
lyses showed that 6 genes related to tumor progression
and 6 genes related to migration were significantly up-
regulated, while DNA methylation-related genes were
significantly downregulated in PMN-MDSCs, compared
with I-MDSCs (Fig. 6f and Additional file 3: Table S2).
These data are consistent with our findings above
(PMN-MDSCs TT vs. NT, Fig. 5; I-MDSCs TT vs. NT,
Fig. 3). In addition, we found that genes associated with
transcriptional regulation (KAT2B, OAS1, UST, CD38,
and CELF2) and signal transduction (CD40 and RPA4)
were differentially expressed in PMN-MDSCs and I-
MDSCs (Fig. 6g). We validated the expression of the
genes above in tumor-infiltrating PMN-MDSCs, I-
MDSCs, and APCs (the latter used as a control) by RT-
PCR. We found that mRNA expression levels in PMN-
MDSCs vs. I-MDSCs (Fig. 6h) were consistent with
RNA-Seq data (Fig. 6g). Statistical significance was
obtained by comparing the mRNA expression levels in
PMN-MDSCs vs. I-MDSCs (Fig. 6h). Interestingly, our
functional network analysis shows that HIF-1 pathway
was active in tumor-infiltrating I-MDSCs (Additional
file 1: Figure S2). These data are consistent with pre-
vious reports demonstrating that HIF-1α is essential
for the infiltration and differentiation of myeloid cells
within the TME [21, 22]. Additionally, we validated
the functional clusters for patients #07 and #08 in
four independent data sets (Additional file 1: Figure
S3). Adhesion molecules, such as integrins, have been
implicated in cancer progression [23]. It was reported
that recruitment of neutrophils (a granulocytic subset
that display similar phenotypic/functional characteris-
tics as PMN-MDSCs) to tumor sites is associated
with increased expression of CD11a integrin on neu-
trophils (also known as LFA-1) [24]. In this study,
our data from RNA-Seq analysis showed that ITGAL
Fig. 5 Differential gene expression of PMN-MDSCs in CRC microenvironment. Hierarchical clustering of PMN-MDSCs from two TT and NT (from
patients #07 and #08) on differentially expressed RNA transcripts from RNA-Seq data. Each column represents a sample and each row represents
a transcript. Expression level of each gene in a single sample is depicted according to color scale (a). Functional categorization of both
upregulated and downregulated top significantly affected transcripts (P value < 0.05) from CLC analysis were analyzed through DAVID separately.
The total number of genes come under both downregulated and upregulated categories were used to calculate the percentage of genes come
under individual functional category. The bar diagram shows the percentage of genes present in each functional category (b). Heat maps show
the TPM representing fold change relative to the mean expression of cell-cell signaling, anti-apoptosis, cell proliferation, transcriptional regulation,
and DNA demethylation in TT, compared with NT (c)
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gene encoding CD11a integrin is upregulated in
tumor-infiltrating PMN-MDSCs, compared with I-
MDSCs (Additional file 1: Figure S4A). We validated
this finding by flow cytometric analysis and showed
that CD11a is highly expressed on tumor-infiltrating
PMN-MDSCs, compared with I-MDSCs (Additional
file 1: Figure S4B).
Genes associated with immunosuppression and myeloid
cell recruitment in CRC tumor tissue are downregulated
upon HDAC or IL-6 inhibition
Our results from RNA-Seq analysis suggested that genes
associated with HDAC activation and IL-6 signaling
pathway were upregulated in tumor-infiltrating I-
MDSCs, compared to those isolated from NT (Figs. 3
and 4). We utilized an explant culture model and
cultured cells isolated from CRC tumor tissues to exam-
ine the effect of HDAC inhibition and IL-6
neutralization on the expression of genes related to
MDSCs function or recruitment. We examined the ex-
pression of four HDAC genes in addition to ARG1 (en-
codes arginase 1 enzyme, which synthesizes nitric
oxide), ITGAL (CD11a, which could be an important
mediator for PMN-MDSCs migration into tumor tissue),
and IDO (encodes indoleamine 2,3-dioxygenase enzyme,
which possess an immunosuppressive function). We also
examined the expression of Wnt5a and Wnt5b as RNA-
Seq data indicated the potential importance of Wnt sig-
naling in I-MDSCs biology/function. Briefly, cells from
CRC tumor tissue were cultured in the presence of LPS
pre-treated or untreated with HDAC inhibitor or anti-
IL-6. HDAC inhibitor and anti-IL-6 mAb were added to
Fig. 6 Differential gene expression and functional network analyses of APCs, PMN-MDSCs, and I-MDSCs in CRC microenvironment. Hierarchical
clustering of APCs and I-MDSCs from two TTs (patients #07 and #08) on differentially expressed RNA transcripts from RNA-Seq data (a). Heat
maps show the TPM representing fold change relative to the mean expression of WNT signaling, SNARE signaling, and JNK pathway activation in
I-MDSCs, compared with APCs (b). Hierarchical clustering of PMN-MDSCs and I-MDSCs from two TTs on differentially expressed RNA transcripts
from RNA-Seq data (c). Heat maps show the TPM representing fold change relative to the mean expression of colorectal cancer-, binding of
HDAC-, cell migration-, NFκB-, and IL-1β production-related genes in PMN-MDSCs, compared with APCs (d). Hierarchical clustering of PMN-MDSCs
and I-MDSCs from two TTs on differentially expressed RNA transcripts from RNA-Seq data (e). Heat map shows the TPM representing fold change
relative to the mean expression of tumor progression-, migration and metastasis-, and DNA methylation-related genes in PMN-MDSCs, compared
with I-MDSCs (f). Heat map shows the TPM representing fold change relative to the mean expression of genes associated with transcriptional
regulation and signal transduction genes in PMN-MDSCs, compared with I-MDSCs (g). The mRNA expression levels for selected genes in tumor-
infiltrating sorted myeloid cells, PMN-MDSCs vs. APCs were validated by RT-PCR (h). The relative gene expression was normalized to β-actin.
Results obtained from six CRC patients, #05, #07, #08, #09, #44, and #53, and expressed as mean ± SEM. N.D. not detected
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cell culture every other day. Of note, LPS was used as a
mitogen to retrieve/enhance the survival of myeloid cells
and induce their activation [25]. On day 5, gene expres-
sion analysis was performed using RT-PCR. The
addition of HDAC inhibitor did not alter the expression
level of HDAC1 and HDAC4 mRNA. However, the ex-
pression of HDAC2 and HDAC3 were reduced, com-
pared to LPS alone (Fig. 7a). HDAC inhibitor
significantly reduced the expression of ARG1, CCR2
(monocyte chemokine receptor), and ITGAL, compared
with LPS alone (Fig. 7b). HDAC inhibition had no ef-
fects on the expression level of IDO, Wnt5a, and Wnt5b
(Fig. 7b). The neutralization of IL-6 significantly reduced
the mRNA levels of ARG1, CCR2, and ITGAL (Fig. 7c).
IL-6 neutralization, however, did no not alter the expres-
sion level of IDO, Wnt5a, and Wnt5b (Fig. 7c). Collect-
ively, these results indicate the importance of HDAC
activation and IL-6 signaling pathways in regulating im-
munosuppression and myeloid cell recruitment to CRC
tumor tissues.
Discussion
Tumor-infiltrating MDSCs are key players, which
negatively modulate the anti-tumor immune response,
and promote angiogenesis and tumor growth/metasta-
sis [26, 27]. Elevated levels of circulating and tumor-
infiltrating PMN-MDSCs and I-MDSCs have been
detected in CRC patients [13, 28]. Additionally, the ex-
pansion of tumor-infiltrating PMN-MDSCs in CRC
patients has been positively correlated with advanced
disease stages and high histological grades [13]. How-
ever, the phenotypic and molecular characteristics of
these MDSCs subsets and their role in CRC progres-
sion remain elusive. Therefore, we investigated the
transcriptional profiles and functional characteristics
of I-MDSCs and PMN-MDSCs within the CRC
microenvironment.
The phenotypic and functional characterization of
MDSCs is widely known to be challenging due to the
heterogeneous nature of these cells [27]. In this study,
we utilized myeloid cell markers to identify the different
Fig. 7 Effect of HDAC or IL-6 inhibition on genes associated with immunosuppression and myeloid cell recruitment in CRC tumor tissues. Cells
isolated from CRC tissue were cultured in the presence of LPS and HDAC inhibitor (100 nM) or anti-IL-6 mAb (2 μg/ml). The relative mRNA
expression levels for HDAC1, HDAC2, HDAC3, HDAC4 (a), and ARG1, CCR2, IDO, ITGAL, Wnt5a, and Wnt5b were determined in the absence or
presence of HDAC inhibitor (b). The relative mRNA expression levels for ARG1, CCR2, IDO, ITGAL, Wnt5a, and Wnt5b were determined in the
absence or presence of anti-IL-6 mAb (c). The relative gene expression was normalized to β-actin. Results obtained from four CRC patients, #26,
#56, #60 and #63, and expressed as mean ± SEM.
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subsets of MDSCs, to calculate their levels in colorectal
tissues as previously described [13]. We found that the
numbers of PMN-MDSCs and I-MDSCs are higher in
colorectal tissues, compared to adjacent normal colorec-
tal tissues. This falls in agreement with other reports
demonstrating the expansion of different MDSCs subsets
in the TME of several malignancies [29, 30].
In this study, transcriptional profiling analyses of I-
MDSCs and PMN-MDSCs revealed novel mechanisms/
signaling pathways, which may govern the MDSCs-
mediated immune suppression and tumor progression in
CRC. Our canonical and functional pathway analyses of
I-MDSCs showed that Wnt, IL-6, and MAPK signaling
pathways are significantly upregulated in TT, compared
with NT, suggesting a role of these pathways in tumor-
infiltrating I-MDSCs within the CRC microenvironment.
The involvement of Wnt signaling in CRC pathogenesis
and progression has been previously established [31–33].
Using a co-culture system with breast cancer cell lines,
Pukrop et al. showed that Wnt signaling is crucial for
macrophage-mediated tumor invasiveness and tumor
cell migration via the production of matrix metallopro-
teinases (MMPs) [34]. Wnt pathway has been shown to
antagonize the recruitment and differentiation of
MDSCs in tumor sites [35]. However, our data suggest a
potential role of Wnt signaling in one MDSCs subset (I-
MDSCs) from CRC tissues. This discrepancy could be
due to the heterogeneity of MDSCs and suggests that
signaling pathways could impact subsets of MDSCs dif-
ferentially. The importance of IL-6 signaling pathway in
MDSCs recruitment and immune suppression has been
previously demonstrated [30]. Using breast cancer
in vitro and in vivo models, Jiang et al. reported that ex-
ogenous IL-6 augments the accumulation of MDSCs
and enhances T cell suppression by inhibiting SOCS3
pathway [19]. In another study, it was demonstrated that
IL-6 upregulates the expression of indoleamine-pyrrole
2,3-dioxygenase (IDO) enzyme via NF-κB activation,
thereby enhancing the immunosuppressive function of
MDSCs in breast cancer [36]. MAPK signaling is an-
other pathway, which we found to be significantly upreg-
ulated in tumor-infiltrating I-MDSCs from CRC
patients. Studies have demonstrated that MAPK signal-
ing pathway is essential for the activation and differenti-
ation of myeloid cells [37, 38]. By combining these
findings, we could anticipate that I-MDSCs in CRC
microenvironment are activated and recruited to tumor
sites where they differentiate into mature phenotypes
and become immune suppressive under the influence of
MAPK- and IL-6-mediated signaling pathways. Target-
ing these pathways in I-MDSCs could suppress their ac-
tivity and reduce their accumulation within the TME,
which in turn may improve the anti-tumor immune re-
sponse and diminish tumor growth/metastasis.
Maintaining transcriptional homeostasis requires a dy-
namic equilibrium of HAT and HDAC activity, where
the former favors gene transcription and the latter sup-
presses it [39]. In pathological conditions, including can-
cer, this equilibrium can be dysregulated by certain
factors, causing either the silencing of tumor suppressor
genes or inducing the expression of genes promoting
tumor growth/metastasis and immunosuppression [40–
43]. Based on functional annotation analyses, we found
that 44% of HDAC- and 29% of DNA methylation-
related genes along with 13% of transcriptional repres-
sors were upregulated in tumor-infiltrating I-MDSCs.
Notably, 90% of HAT-related genes were downregulated
in tumor-infiltrating I-MDSCs. These data indicate that
transcriptional regulation in tumor-infiltrating I-MDSCs
could be controlled by DNA methylation and post-
translational histone modifications, possibly, mediated
by HDAC activation and the suppression of HAT activ-
ity. Such epigenetic changes can be responsible for
downregulating genes involved in tumor suppression or
T cell activation [44, 45]. Unlike I-MDSCs, we found
that DNA methylation- and HDAC-related genes were
downregulated in tumor-infiltrating PMN-MDSCs, sug-
gesting that the regulation of gene expression in these
MDSCs subsets is governed via differing epigenetic
mechanisms. Therefore, we could propose a novel thera-
peutic approach by which specific populations of
MDSCs can be targeted in CRC. Rather than endemic
targeting of MDSCs, targeting specific populations of
MDSCs by the use of appropriate epigenetic modifiers
could be employed to design a well-targeted therapy for
CRC patients.
Interestingly, we found that genes of JNK- and
SNARE-mediated pathways were upregulated in tumor-
infiltrating I-MDSCs, compared with APCs. These path-
ways could have a functional impact on I-MDSCs activ-
ity and CRC progression. Han et al. reported the
upregulation of JNK pathway in tumor-infiltrating mye-
loid cells, from mouse liver cancer model, is crucial for
promoting disease pathogenesis and progression [46].
Based on animal studies, it was suggested that specific
targeting of JNK in myeloid cells could offer therapeutic
benefits for patients with hepatocellular carcinoma [46].
In addition, JNK signaling pathway in myeloid cells has
been associated with the production of Treg chemo-
attractant agents, such as CCL17 and CCL22 [47], indi-
cating its potential role in MDSCs suppressive function.
SNARE proteins have been associated with the regula-
tion of cytokine secretion macrophages and dendritic
cells, and inhibition of phagocytosis and antigen presen-
tation [48], suggesting their potential function in I-
MDSCs via similar means.
Our functional annotation and transcriptomic analyses
showed that genes related to cell-cell signaling, cell
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proliferation, anti-apoptosis, and cellular migration were
upregulated in tumor-infiltrating PMN-MDSCs. These
data imply the potential of PMN-MDSCs function in
CRC progression, which may involve the enhancement
of tumor growth/metastasis and immune cell trafficking.
Consistent with this, Ouzounova et al. reported that en-
richment of lung TME with activated PMN-MDSCs was
associated with increased expression of genes promoting
tumor growth and metastasis [49]. Within the CRC
microenvironment, we found that NF-κB- and IL-1β
production-related genes were upregulated in PMN-
MDSCs, compared with APCs. It has been reported that
tumor-derived IL-1β enhances MDSCs infiltration, accu-
mulation, and immunosuppressive activity within the
TME, thereby promoting tumor progression [38, 50].
Another study by Tu et al. showed that IL-1β overex-
pression induces gastric inflammation and cancer
through the activation of NF-κB, resulting in the accu-
mulation of MDSCs within tumor sites [51]. In turn,
NF-κB activation exerts an anti-inflammatory function
on MDSCs, enhances MDSCs infiltration in tumor sites
by regulating chemotaxis [52], and induces immunosup-
pression by upregulating the expression of IDO [36].
Therefore, we could suggest that the suppressive activity
of tumor-infiltrating PMN-MDSCs in CRC is positively
regulated by IL-1β/NF-κB signaling pathway.
Hypoxia is a common feature of solid tumors, which
arise from reduced levels of oxygen and nutrient supply
as a result of tumor outgrowth [53]. Hypoxia can medi-
ate resistance to chemotherapy, promote tumor metasta-
sis, and enhance MDSCs accumulation within TME
[53]. Kumar et al. reported that the upregulation of HIF-
1α enhances the immunosuppressive activity of myeloid
cells and promotes the rapid conversion of MDSCs to
tumor-associated macrophages (TAMs) [53] via the up-
regulation of iNOS and arginase [35]. In addition, HIF-
1α can bind to the promotor of PD-L1, co-inhibitory re-
ceptor, and increase its expression on myeloid cells has
been demonstrated [35]. In our study, the upregulation
of HIF-1 pathway was more profound in I-MDSCs (im-
mature myeloid cells), compared with PMN-MDSCs
(mature myeloid cells), suggesting the potential import-
ance of this pathway in I-MDSCs function/biology. On
these grounds, we could speculate that I-MDSCs differ-
entiate into the mature phenotype, TAMs, by upregulat-
ing HIF-1 pathway. In renal carcinoma, the upregulation
of HIF-1 and constitutive activation of HIF-1 pathway
occur due to a loss of tumor suppressor gene/function,
von Hippel-Lindau (VHL), either by mutation or hyper-
methylation [54]. This subsequently results in the ex-
pression of angiogenic factors and genes promoting
disease oncogenesis [54]. This is consistent with the
finding that I-MDSCs regulate gene transcription by
DNA methylation, which might be associated with
tumor suppressor gene silencing. Employing therapeutic
strategies to target HIF-1 could be beneficial in reducing
the suppressive activity of MDSCs and the differenti-
ation of TAMs, which ultimately should improve anti-
tumor responses in patients. Using an ex vivo approach,
we confirmed the importance of HDAC activation and
IL-6 signaling pathway in regulating the expression of
genes associated with MDSC suppressive function, such
as ARG1, and genes related to myeloid cell chemotaxis,
such as CCR2 and ITGAL.
Conclusions
This study provides novel insights into the epigenetic
mechanisms and signaling pathways regulating the tran-
scriptional profile, and perhaps the function, of different
myeloid cell subsets within the CRC TME. Furthermore,
findings from this study indicate the importance of
HDAC activation and IL-6 signaling pathway in regulat-
ing MDSC suppressive function and perhaps the recruit-
ment of MDSCs to the CRC microenvironment.
Methods
Sample collection and storage
Tumor tissues (TT) and paired, adjacent normal tissues
(NT) were obtained from 27 CRC patients who under-
went surgery at Hamad Medical Corporation, Doha,
Qatar. All patients included in the study were
treatment-naïve prior to surgery and provided written
informed consent prior to sample collection. Table 1
shows the clinical and pathological characteristics of all
participating patients. All experiments were performed
in accordance with relevant guidelines and regulations.
This study was executed under ethical approvals from
Hamad Medical Corporation, Doha, Qatar (protocol no.
MRC-02-18-012) and Qatar Biomedical Research Insti-
tute, Doha, Qatar (protocol no. 2018-018). Tissue speci-
mens were cut into small pieces and frozen in 1 ml of
freezing medium (10% dimethylsulphoxide (DMSO;
Sigma-Aldrich, Missouri, USA), 50% fetal calf serum
(FCS; Hyclone, GE Healthcare Life Sciences, Utah,
USA), and 40% RPMI-1640 medium (Life Technologies,
New York, USA)), then stored in liquid nitrogen to be
used in batches for subsequent analyses.
Cell dissociation
Cells were isolated from TT by mechanical disaggrega-
tion. Briefly, tissues frozen in freezing media were
thawed and washed with phosphate-buffered saline
(PBS) and then mechanically cut into small pieces (~ 2–
4 mm) using a surgical scalpel. Further disaggregation
was performed on gentleMACS dissociator (Miltenyi
Biotech, Bergisch Gladbach, Germany) without using
any enzymes. The cell suspension was then passed
through a 100-μM cell strainer to remove debris and
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aggregates. The single cell suspension was washed with
PBS and stained for flow cytometric analyses and FACS
sorting.
Multi-parametric flow cytometry
Cells isolated from tissues were washed with PBS and
re-suspended in 100 μl flow cytometry staining buffer
(PBS with 1% FCS and 0.1% sodium azide). Fc receptors
(FcR) were first blocked using FcR Blocker (Miltenyi
Biotech, Bergisch Gladbach, Germany). 7-AAD viability
dye (eBioscience, San Diego, USA) was used to gate live
cells. Cells were then stained with cell surface antibodies
against CD33-Fluorescein isothiocyanate (clone HIM3-4;
BD Biosciences, Oxford, UK), CD14-phycoerythrin-Cy7
(clone M5E2; BD Biosciences), CD15-allophycocyanin
(clone HI98; BioLegend, San Diego, USA), HLA DR-
phycoerythrin (clone G46-6; BD Biosciences) or CD11a-
phycoerythrin (clone G43-25B; BD Pharmingen, San
Jose, USA) and incubated at 4 °C for 30 min. Cells were
then washed twice with flow cytometry staining buffer
and data were acquired by BD LSRFortessa X-20 flow
cytometer (BD Biosciences).
For sorting, cells were re-suspended in Pre-Sort buffer
(BD Biosciences). BD FACSAria III SORP cell sorter
with BD FACSDiva software (BD Biosciences) was used.
Applicable measures were taken to ensure minimal
sorter-induced cell stress (SICS). Data analyses were per-
formed on FlowJo V10 software (FlowJo, Ashland, USA).
Cell culture
Cells were isolated from TT by mechanical disaggrega-
tion, as described above. 0.5 × 106 cells per well were
seeded onto a 24-well tissue culture-treated plate and
cultured in complete RPMI-1640 medium (Life Tech-
nologies). Cells were untreated or pre-treated with 100
nM of HDAC inhibitor Vorinostat (SAHA, MK0683,
Selleckchem, Texas, USA) or 2 μg/ml of anti-IL-6 mono-
clonal antibody (Sino Biological, Beijing, China) [55].
After a 2-h incubation period, 100 ng/ml of Lipopolysac-
charides (LPS from E. coli, Sigma-Aldrich) was added to
all the wells. Cells were kept in a humidified incubator
at 37 °C in 5% CO2 for 5 days. Every other day, HDAC
inhibitor and anti-IL-6 mAb were added to the wells at
the same concentration. Cells were harvested on day 5
post treatment for RNA extraction.
Library preparation
Pure 1000 CD33+HLA-DR−CD14−CD15− (I-MDSCs),
CD33+HLA-DR−CD14−CD15+ (PMN-MDSCs) and
CD33+HLA-DR+CD14+CD15− (APCs) cells were sorted
from TT and NT. Cells were initially sorted from six
CRC NT and TT samples. Library preparation and sub-
sequent RNA-Seq were succeeded in subsets from two
patients only (#07 and #08). This could be due to the
lower percentage and lower expression level of MDSC
subsets in some TT and NT samples. Similarly, CTLA-
4+ and CTLA-4− Tregs from head and neck cancer pa-
tients were compared in very small number of samples
[56]. The cDNA libraries were generated using QIAseq
FX Single Cell RNA Library Kit (Qiagen, Hilden,
Germany) following the manufacturer’s instructions.
Briefly, sorted cells were spun down and lysed immedi-
ately. The gDNA was then removed by using gDNA
Wipeout buffer (Qiagen). The gDNA-removed lysates
were used to generate double-stranded DNA, which
were subsequently amplified using REPLI-g sc SensiPhi
DNA polymerase. Small fractions of amplified products
were cleaned using PureLink PCR Purification Kit
(Thermo Fisher Scientific, Massachusetts, USA) and
quality checked using Agilent High Sensitivity DNA Kit
(Agilent Technologies, California, USA). The quality
passed DNA (> 2000 bp) were quantified using Qubit
dsDNA HS Assay Kit (Invitrogen, California, USA). Five
hundred nanograms to 1 μg DNA was enzymatically
fragmented and ligated using paired adaptors. DNA was
further purified using Agencourt AMPure XP beads
(Beckman Coulter, California, USA). The yield and size
distribution of libraries (500–1000 bp) were determined
using Qubit dsDNA HS Assay Kit (Invitrogen) and Agi-
lent High Sensitivity DNA Kit (Invitrogen).
RNA-sequencing data analyses
Pair end reads were quality-trimmed and were aligned
to the hg19 human reference genome in CLC Genomics
Workbench-12 (Qiagen) using default settings [57, 58].
The abundance of the expression of transcripts was
measured as the score of TPM (transcripts per million)
mapped reads in CLC Genomics Workbench 12. Abun-
dance data were subsequently subjected to differential
gene expression using built-in statistical analyses recom-
mended in CLC Genomics protocol with 2.0-fold change
and P value cutoff < 0.05.
Functional annotation analyses using DAVID platform
Database for Annotation, Visualization, and Integrated
Discovery (DAVID) platform was used to analyze the
functional annotation, in addition to Kyoto Encyclopedia of
genes and Genomes (KEGG)/BioCarta network [59, 60].
The “Functional Annotation,” “KEGG pathway,” and “Bio-
Carta” in the online version of DAVID 6.8 was performed
(https://david.ncifcrf.gov/) by matching with Homo sapiens
gene list. The upregulated genes and downregulated genes
were trimmed with both expression consistency of individ-
ual genes (> 2 FC) and P value cutoff < 0.05. The upregu-
lated genes and downregulated genes were uploaded
separately and focused on the Gene-Ontology, Functional-
Categories, Gene-Annotations and Pathways. To visualize
the network pathways, we used both KEGG and BioCarta.
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The related genes from functional analyses were depicted
as heat plots.
RNA extraction and reverse transcription
Total RNA was extracted from the sorted tumor-
infiltrating myeloid cell populations (APCs, I-MDSCs
and PMN-MDSCs) isolated from six CRC patients (#05,
07, 08, 09, 44, and 53), using RNAqueous-Micro Total
RNA isolation Kit (Thermo Fisher Scientific). Total
RNA was also extracted from cultured cells isolated
from tumor tissue of four CRC patients (#26, 56, 60, and
63) using Total RNA Purification Plus Micro Kit (Nor-
gen, Ontario, Canada). RNA was then amplified using
5X MessageAmp II aRNA Amplification Kit (Thermo
Fisher Scientific). RNA concentrations before and after
amplification were determined by Qubit RNA HS and
Broad Range Assay Kit, respectively (Invitrogen). One
microgram of RNA was reverse transcribed into cDNA
using QuantiTect Reverse Transcription Kit (Qiagen).
Quantitative real-time reverse transcriptase PCR (qRT-PCR)
qRT-PCR was performed using QuantStudio 6/7 Flex
Real-time PCR system (Applied Biosystems, California,
USA) for KAT2B, CD40, RPA4, UST, CELF2, CD38,
OAS1, HDAC1, HDAC2, HDAC3, HDAC4, ARG1, IDO,
ITGAL, CCR2, Wnt5a, Wnt5b, and β-actin with
PowerUp SYBR Green Master Mix (Applied Biosystems).
Quantification of relative gene expression was deter-
mined, using 2−ΔΔCT, and normalized to β-actin. Se-
quences for the primers are shown in Additional file 2:
Table S1.
Statistical analyses
Statistical analyses were performed using GraphPad
Prism 8 software (GraphPad Software, California, USA).
Paired t tests were performed on samples that passed
the Shapiro-Wilk normality test and Mann-Whitney
tests were performed for samples that did not show nor-
mal distribution. A P value of > 0.05 was considered sta-
tistically non-significant. The P values are represented as
follows: ***P < 0.001, **P < 0.01, and *P < 0.05. Data are
presented as mean ± standard error of the mean (SEM).
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13148-020-0808-9.
Additional file 1: Figure S1. Adherent junction pathway in tumor-
infiltrating PMN-MDSCs. The upregulated genes in PMN-MDSCs from 2
patients were uploaded in DAVID to identify the biological pathways. Ad-
herent junction is the top KEGG pathway regulated in PMN-MDSCs, com-
pared with APCs within the TME. The black ovals highlight the KEGG
identified functional pathways that are regulated by PMN-MDSCs, within
the TME. The functional consequences of related genes are shown in red.
Figure S2. HIF-1 signaling pathway in tumor-infiltrating I-MDSCs. The
downregulated genes in PMN-MDSCs, compared with I-MDSCs from two
patients were uploaded in DAVID to identify the biological pathways. HIF-1
signaling is the top KEGG pathway regulated in I-MDSCs, within the TME.
The black ovals highlight the KEGG identified functional pathways that are
regulated by I-MDSCs, within the TME. The functional consequences of re-
lated genes are shown in red. Figure S3. Validation of differential gene ex-
pression and functional network analyses of APCs, PMN-MDSCs and I-
MDSCs in CRC patients. Heat maps show the TPM representing fold change
to the mean expression of WNT signaling, SNARE signaling and JNK path-
way activation in I-MDSCs (A). Heat maps show the TPM representing fold
change relative to the mean expression of colorectal cancer-, cell migration-
, NFκB-, IL-1β production-related genes in PMN-MDSCs, compared with
APCs (B). Heat map shows the TPM representing fold change relative to the
mean expression of tumor progression-, migration and metastasis- and DNA
methylation-related genes in PMN-MDSCs (C). Results obtained from four
CRC patients (#09, #12, #13, and #16). Figure S4. CD11a expression in
tumor-infiltrating PMN-MDSCs. Heat map shows the TPM representing fold
change relative to the mean expression of CD11a gene (ITGAL) in PMN-
MDSCs (A). Cells isolated from TT of #07 and #08 patients were stained for
myeloid cell markers and CD11a, and analyzed by flow cytometry.
Representative flow cytometric plots show the gating strategy employed to
identify I-MDSCs and PMN-MDSCs expressing CD11a (B).
Additional file 2: Table S1. Gene cluster analysis.
Additional file 3: Table S2.: DAVID analysis
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